Fluticasone propionate: a potent inhaled corticosteroid for the treatment of asthma.

Abstract:

:Fluticasone propionate (FP) is a potent inhaled corticosteroid (ICS) for the treatment of asthma. It is currently marketed in both the United States (as Flovent) and Europe (as Flixotide). Fluticasone is available in both aerosolised metered dose inhaler (MDI) and dry powder devices, with dosages ranging from 44-500 micrograms/puff. FP has been extensively studied in both children and adults; efficacy has been documented across the entire spectrum of asthma severity, including corticosteroid-dependent disease. Clinical data with FP strongly corroborates the in vitro pharmacokinetic and pharmacodynamic studies that FP is at least twice as potent as beclomethasone dipropionate (BDP), budesonide (BUD) or triamcinolone acetonide (TAA). Both objective (lung function) and subjective (symptoms, beta-agonist use and quality of life) outcomes are improved with FP treatment. Extensive post-marketing surveillance with FP suggests that it is more cost-effective than BUD and flunisolide (FLU) when analysed by an overall healthcare cost perspective. Most of the benefits arise from decreased hospitalizations, emergency room visits and physician-office visits. Extensive safety data with FP documents no clinically meaningful effects on bone mass, nor impairment of growth velocity in children. Considering the efficacy and safety data along with the ability to optimise patient's asthma therapy using the delivery devices and strengths available, FP has become a leader in the ICS marketplace to date.

authors

Staresinic AG,Sorkness CA

doi

10.1517/14656566.1.6.1227

keywords:

subject

Has Abstract

pub_date

2000-09-01 00:00:00

pages

1227-44

issue

6

eissn

1465-6566

issn

1744-7666

journal_volume

1

pub_type

杂志文章,评审
  • Opioids in the treatment of postoperative pain: old drugs with new options?

    abstract::New approved options with opioids in the postoperative setting may include new ways of administration, new combinations with other drugs and new opioid drugs. Newly approved devices for administration include sublingual sufentanil dispenser and transdermal iontophoretic fentanyl, with the purpose of almost mimicking t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2014.879292

    authors: Raeder J

    更新日期:2014-03-01 00:00:00

  • New treatment options for panic disorder: clinical trials from 2000 to 2010.

    abstract:INTRODUCTION:Panic disorder (PD) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks. PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide. PD should be treated effectively as soon as the symptoms emerge because the long...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.562200

    authors: Freire RC,Hallak JE,Crippa JA,Nardi AE

    更新日期:2011-06-01 00:00:00

  • Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.

    abstract:INTRODUCTION:Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs). However, they require special storage and transportation and remission is observed in ∼ 30%. Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK),...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.854771

    authors: Yamaoka K,Tanaka Y

    更新日期:2014-01-01 00:00:00

  • Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

    abstract:INTRODUCTION:Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier sta...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1496237

    authors: Cretin B

    更新日期:2018-08-01 00:00:00

  • Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?

    abstract:INTRODUCTION:When estimating the cost-effectiveness or budget impact of chronic obstructive pulmonary disease (COPD) medication, it is common practice to use trial data for clinical inputs. However, such inputs do not always reflect the real-world situation. Previous reviews recognized the need for taking real-world da...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2021.1873953

    authors: Fens T,Zhou G,Postma MJ,van Puijenbroek EP,van Boven JFM

    更新日期:2021-01-13 00:00:00

  • Combination strategies for pain management.

    abstract::At least two factors relating to pain management using oral analgesics suggest that combination strategies merit consideration: many pains arise from more than one physiological cause and current analgesics have adverse effect profiles that might be reduced by combination with another agent in smaller doses or with le...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.10.1697

    authors: Raffa RB,Clark-Vetri R,Tallarida RJ,Wertheimer AI

    更新日期:2003-10-01 00:00:00

  • Bipolar disorders: new approaches to therapy.

    abstract::This article reviews the evidence supporting different somatic treatment strategies in the acute and maintenance treatment phases of bipolar disorder. Bipolar affective disorder is a chronic disorder with a life time incidence of 0.3 - 1.5/100 [1]. Severe affective disorder is associated with a risk of completed suici...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.4.601

    authors: Watson S,Young AH

    更新日期:2001-04-01 00:00:00

  • Drug interactions in the management of HIV infection.

    abstract::The availability of antiretroviral therapy has significantly reduced the morbidity and mortality of HIV infection. In addition, improved treatment of opportunistic infections and comorbidities common to patients with HIV is further prolonging the lives of patients. Improvement in the treatment of HIV has led to a sign...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.2.233

    authors: Robertson SM,Penzak SR,Pau AK

    更新日期:2005-02-01 00:00:00

  • Cardiac sodium channels and inherited electrophysiological disorders: an update on the pharmacotherapy.

    abstract:INTRODUCTION:Since the recognition of inherited sodium (Na(+)) channel disease, the cardiac Na(+) channel has been extensively studied. Both loss-of-function and gain-of-function mutations of the cardiac Na(+) channel are associated with cardiac arrhythmia and sudden cardiac death. Pathophysiological mechanisms that ma...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.936380

    authors: van Hoeijen DA,Blom MT,Tan HL

    更新日期:2014-09-01 00:00:00

  • Treating diabetic ulcers.

    abstract:INTRODUCTION:Diabetic foot ulceration is a serious secondary complication of diabetes mellitus and the most common cause of hospitalization in diabetic patients. The etiology of diabetic foot ulcerations is complex due to their multifactorial nature. Thus, addressing all of the factors involved remains instrumental in ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.530658

    authors: Tecilazich F,Dinh T,Veves A

    更新日期:2011-03-01 00:00:00

  • Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.

    abstract:BACKGROUND:This subgroup analysis of STELLA-LONG TERM interim data explored the long-term safety and efficacy of ipragliflozin in non-elderly vs. elderly Japanese type 2 diabetes mellitus (T2DM) patients. RESEARCH DESIGN AND METHODS:STELLA-LONG TERM is an ongoing 3-year prospective surveillance study of Japanese T2DM ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1434145

    authors: Maegawa H,Tobe K,Tabuchi H,Nakamura I,Uno S

    更新日期:2018-03-01 00:00:00

  • The optimal combination therapy for the treatment of early rheumatoid arthritis.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune condition traditionally viewed as a severe destructive disease affecting physical health and global wellbeing. The treatment strategies for RA have changed in the last decades from mainly symptomatic towards a more vigorous and targeted approac...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1056735

    authors: De Cock D,Van der Elst K,Meyfroidt S,Verschueren P,Westhovens R

    更新日期:2015-01-01 00:00:00

  • Systemic retinoids in chemoprevention of non-melanoma skin cancer.

    abstract:BACKGROUND:The incidence of non-melanoma skin cancer is increasing worldwide. Systemic retinoids are useful for the chemoprophylaxis of non-melanoma skin cancers. Retinoids have pleiotropic effects, but their exact cancer chemopreventive mechanism is still not clear. OBJECTIVE:The aim of this study was to review publi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.8.1363

    authors: Lens M,Medenica L

    更新日期:2008-06-01 00:00:00

  • Ziprasidone for maintenance treatment of bipolar I disorder in adults.

    abstract:INTRODUCTION:Antipsychotic drugs are increasingly used in the maintenance treatment of bipolar disorder. This review addresses the evidence supporting the use of one of these medications for this indication in order to place available data in perspective for the clinician. AREAS COVERED:The approval of ziprasidone for...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.2011.563237

    authors: Dubovsky SL,Dubovsky AN

    更新日期:2011-04-01 00:00:00

  • Management of insomnia in alcohol use disorder.

    abstract::Introduction: Insomnia has been implicated in the development, maintenance, worsening, and relapse of alcohol use disorder (AUD).Areas covered: The authors review the possible pharmacological and non-pharmacological treatment options of insomnia for patients with alcohol-use disorder and provide their expert opinion.E...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1705279

    authors: Geoffroy PA,Lejoyeux M,Rolland B

    更新日期:2020-02-01 00:00:00

  • 1st International Conference on Panic Attacks: diversity of theories and treatments. september 5-8, 2003, London.

    abstract::The 1st International Conference on Psychophysiology of Panic Attacks focused on the diversity of treatments and theories in this complex condition. Experimental research topics were featured, as well as treatment strategies, case studies and patient perspectives. The conference aimed to create a strong multi-cultural...

    journal_title:Expert opinion on pharmacotherapy

    pub_type:

    doi:10.1517/14656566.5.4.977

    authors: Perry D

    更新日期:2004-04-01 00:00:00

  • Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.

    abstract:BACKGROUND:Lopinavir is a protease inhibitor with high specificity for HIV-1 protease formulated with ritonavir. Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) is highly effective as a component of highly active antiretroviral therapy (HAART) regimens for HIV-1 infection. OBJECTIVE:In this articl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.13.2363

    authors: Barragan P,Podzamczer D

    更新日期:2008-09-01 00:00:00

  • Pharmacoeconomic considerations in anticoagulant drug use.

    abstract::Anticoagulants are used for the prevention and treatment of venous thromboembolism and for the secondary prevention of stroke and myocardial infarction. The list of available anticoagulants includes unfractionated heparin, low molecular weight heparins, fondaparinux, warfarin and the direct thrombin inhibitors. Numero...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.8.989

    authors: Hawkins D,Huston SA

    更新日期:2006-06-01 00:00:00

  • The use of alpha-adrenoceptor antagonists in lower urinary tract disease.

    abstract::alpha-adrenoceptor antagonists have traditionally been used in the treatment of hypertension but in recent years they have become increasingly common in the treatment of benign prostatic enlargement (BPE), where they reduce the 'dynamic' component of bladder outlet obstruction and appear to have additional actions to ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.2.167

    authors: Chess-Williams R

    更新日期:2002-02-01 00:00:00

  • Pharmacological treatment for insomnia in patients with major depressive disorder.

    abstract:INTRODUCTION:Insomnia in Major Depressive Disorder (MDD) is highly prevalent and associated with increased suffering and functional impairment. Effective, evidence-based treatments for insomnia in MDD are an unmet need in clinical practice. AREAS COVERED:Herein, the authors provide a review of the clinical correlates,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1614562

    authors: Brietzke E,Vazquez GH,Kang MJY,Soares CN

    更新日期:2019-08-01 00:00:00

  • Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures.

    abstract::Injectable and absorbable contrast media for the use in radiology, all of which contains iodine as an essential component, has been, and continues to be, one of the main sources of agents which cause hospital-acquired renal failure. Although numerous methods have been explored to prevent renal contrast damage, radioco...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.5.639

    authors: Mintz EP,Gruberg L

    更新日期:2003-05-01 00:00:00

  • The pharmacological management of cardiovascular disease in people living with HIV (PLWH).

    abstract::ABSTARCT Introduction: Cardiovascular disease (CVD) continues to be an essential cause of morbidity and mortality among people living with human immunodeficiency virus infection (PLWH). Since the bulk of cardiovascular risk (CVR) factors are shared between PLWH and the general population, prevention and treatment stra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1856075

    authors: Corbacho N,Mur I,Molas ME,Vidal F,Domingo P

    更新日期:2021-01-04 00:00:00

  • Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy.

    abstract::Amyotrophic [corrected] lateral sclerosis (ALS) is a progressive degenerative condition of motor neurons that is ultimately fatal. Even though scientific discovery over the past few decades has led to a greater understanding of the pathogenic mechanisms of ALS, effective pharmacotherapy intended to slow, arrest or rev...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.4.735

    authors: Weiss MD,Weydt P,Carter GT

    更新日期:2004-04-01 00:00:00

  • Paracetamol and asthma.

    abstract::Paracetamol (acetaminophen) is one of the over-the-counter analgesics that is used frequently for the self-management of some of the common disorders. There seems to be two types of relations between paracetamol and asthma - paracetamol intolerance leading to bronchospasm in analgesic-induced asthmatics; and the relat...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.1.13

    authors: Karakaya G,Kalyoncu AF

    更新日期:2003-01-01 00:00:00

  • Role of aprotinin in the management of patients during and after cardiac surgery.

    abstract::Management of patients undergoing cardiac surgery has evolved in recent years as more is understood about the physiological changes and responses that occur during and after cardiopulmonary bypass (CPB). In particular, our understanding of the mechanisms involved in haemostasis and in the inflammatory response to bypa...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.7.1353

    authors: Punjabi PP,Wyse RK,Taylor KM

    更新日期:2000-12-01 00:00:00

  • Pharmacotherapy for knee osteoarthritis: current and emerging therapies.

    abstract:INTRODUCTION:Osteoarthritis (OA) is the leading cause of pain, loss of function and disability in the elderly, with the knee being the most impactful joint affected. Currently, there is still no 'cure' in OA treatment. AREAS COVERED:The authors review the current and emerging therapies for knee OA including traditiona...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1732924

    authors: Cao P,Li Y,Tang Y,Ding C,Hunter DJ

    更新日期:2020-05-01 00:00:00

  • Current chemotherapy options for thymic epithelial neoplasms.

    abstract::Thymomas and thymic carcinoma are rare neoplasms. Surgical resection is the cornerstone of effective therapy. Stage I disease is effectively treated by complete surgical resection. The role of radiation therapy in completely resected stage II disease remains controversial. Adjuvant radiation therapy is useful for loca...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.7.1169

    authors: Papadopoulos KP,Thomas CR Jr

    更新日期:2005-06-01 00:00:00

  • Pediatric HIV: new opportunities to treat children.

    abstract:BACKGROUND:Treating HIV-infected children remains a challenge due to a lack of treatment options, appropriate drug formulations and, in countries with limited resources, insufficient access to diagnostic tests and treatment. OBJECTIVE:To summarize current data concerning new opportunities to improve the treatment of H...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903012377

    authors: Van der Linden D,Callens S,Brichard B,Colebunders R

    更新日期:2009-08-01 00:00:00

  • Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.

    abstract:BACKGROUND:Alzheimer's disease is thought to be caused by increased formations of neurotoxic amyloid beta (A beta) peptides, which give rise to the hallmark amyloid plaques. Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit. OBJECTIVE:This paper reviews the pharmacology and c...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903044982

    authors: Henley DB,May PC,Dean RA,Siemers ER

    更新日期:2009-07-01 00:00:00

  • Flecainide acetate for the treatment of atrial and ventricular arrhythmias.

    abstract:INTRODUCTION:Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. The clinical development program of flecainide provided good data on its antiarrhythmic effect for the prevention of ventricular and supraventricular arrhythmias. The Cardiac Arrhythmia Suppression Trial (CAST), conducted to test...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.759212

    authors: Apostolakis S,Oeff M,Tebbe U,Fabritz L,Breithardt G,Kirchhof P

    更新日期:2013-02-01 00:00:00